Arbutus Biopharma Corp ABUS is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's MRNA appeal to invalidate two of Arbutus' patents on drug-delivery technology.
A federal appeals court upheld the ruling to not invalidate patents held by Arbutus. The court ruled that Moderna didn't have the standing to appeal.
Following the ruling, Arbutus may be eligible for royalties from sales of Moderna's COVID-19 vaccine.
See Also: Why Moderna Shares Are Sliding Today
Arbutus is a biopharmaceutical company focused on discovering, developing and commercializing cures for patients suffering from Hepatitis B infections.
ABUS Price Action: Arbutus has traded as high as $5.87 and as low as $2.43 over a 52-week period.
The stock was up 66.50% at $5.33 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
